CJC-1295 DAC

1. Quick Facts

Category: Growth Hormone Releasing Hormone (GHRH) Analog

Risk Level: Moderate/High

Research Status: Human Clinical Research

Administration: Subcutaneous Injection

Typical Frequency: Weekly or Split Twice Weekly

Estimated Half-Life: Approximately 5–8 Days

Primary Research Interest: Growth Hormone Signaling / Recovery / IGF-1 Support

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. CJC-1295 DAC is a biologically active GHRH analog capable of significantly altering growth hormone, IGF-1, metabolic, and recovery signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

CJC-1295 DAC is an experimental long-acting Growth Hormone Releasing Hormone (GHRH) analog researched for its potential effects on sustained growth hormone signaling, recovery enhancement, IGF-1 support, and body composition pathways.

Unlike shorter-acting GHRH analogs, CJC-1295 DAC utilizes Drug Affinity Complex (DAC) technology to dramatically prolong circulation time and extend downstream endocrine effects. Research interest commonly centers around recovery optimization, sleep quality, body composition, and sustained growth hormone pathway activation.

What People Commonly Claim

Continuous elevation of growth hormone and IGF-1 with only one injection per week
Improved recovery, muscle gain, and fat loss
Enhanced sleep quality and tissue repair
A more convenient alternative to shorter-acting growth hormone secretagogues
Superior results when combined with compounds such as Ipamorelin

What the Literature Actually Shows

CJC-1295 DAC was developed to prolong the activity of a GHRH analog through Drug Affinity Complex (DAC) technology.
Human studies have demonstrated prolonged elevations in growth hormone and IGF-1 levels following administration.
The compound appears capable of producing sustained endocrine effects lasting several days after a single dose.
Evidence supporting improvements in muscle gain, athletic performance, or recovery in healthy individuals remains limited.
Many claims regarding body composition, performance enhancement, and peptide stacking strategies originate from anecdotal reports rather than controlled clinical trials.

CKF Note: CJC-1295 is available in both DAC and No DAC (Modified GRF 1-29) forms. Although the compounds share a common origin, their pharmacokinetics and typical administration protocols differ substantially. Readers interested in the shorter-acting pulsatile version should review the CJC-1295 No DAC Tide Table.

3. Reconstitution Guide

Vial Size: 5 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 2 mL
Final Concentration: 2.50 mg/mL

At this concentration:
• 1 mg = 0.400 mL (40 units)
• 2 mg = 0.800 mL (80 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

CJC-1295 DAC is most commonly administered as a long-acting subcutaneous injectable GHRH analog.

Primary Route: SubQ Injection
Preferred Timing: Weekly or split into twice-weekly administration
Administration Notes: Frequently researched in conjunction with GHRP compounds and recovery-focused protocols.

5. Common Research Protocols

Product Strength: 2.50 mg/mL
Typical Delivered Amount: 1–2 mg weekly total
Frequency: Weekly or split into twice-weekly administration
Cycle Length: 3–6 months on / 1–3 months off
Special Notes: CJC-1295 DAC is commonly discussed as a long-acting GHRH analog designed to sustain elevated growth hormone and IGF-1 signaling over extended periods. Compared to shorter-acting secretagogues, the DAC version may produce more stable background elevation rather than sharp pulsatile peaks. Researchers frequently combine it with GHRPs such as Ipamorelin, GHRP-2, or Hexarelin in an attempt to amplify growth hormone release pathways. Because prolonged elevation of growth hormone and IGF-1 may increase risks related to insulin sensitivity, water retention, and tissue growth signaling, conservative dosing and periodic reassessment are commonly emphasized.

6. Mechanism of Action

CJC-1295 DAC functions by stimulating growth hormone releasing hormone pathways and prolonging growth hormone signaling activity through DAC-mediated half-life extension.

Growth hormone signaling enhancement
IGF-1 pathway support
Recovery signaling support
Potential sleep-quality enhancement
Metabolic pathway modulation
Extended-duration peptide activity

The DAC modification substantially increases peptide duration compared to shorter-acting GHRH analogs by promoting albumin binding and prolonged circulation.

7. Potential Benefits

Potential increase in growth hormone signaling
Enhanced recovery support
Possible sleep-quality improvements
Potential body composition support
Possible connective tissue recovery support
Potential synergistic effects with GHRP compounds

8. Potential Risks / Side Effects

Moderate/High

Water retention
Numbness or tingling
Fatigue
Potential insulin sensitivity changes
Elevated IGF-1 signaling
Possible joint discomfort
Potential tissue growth concerns with prolonged excessive use

9. Half-Life

CJC-1295 DAC is commonly discussed as having a half-life in the range of approximately 5–8 days, though downstream endocrine effects may persist substantially longer.

The DAC modification allows sustained receptor activity and prolonged elevation of downstream growth hormone and IGF-1 signaling pathways.

Unlike CJC-1295 No DAC (Modified GRF 1-29), which produces short-lived pulses lasting minutes to hours, the DAC version was specifically engineered to create prolonged endocrine stimulation from infrequent administration.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

Active cancer concerns
Uncontrolled diabetes
Pregnancy or breastfeeding
Known hypersensitivity to peptide compounds
Use alongside multiple hormone-modulating compounds without supervision

12. Further Study

CJC-1295 DAC possesses a modest but meaningful human research base demonstrating prolonged growth hormone and IGF-1 elevation. While many online discussions focus on muscle gain, recovery, and performance enhancement, the strongest evidence currently supports its endocrine effects rather than specific athletic outcomes.

Tier 1 — Essential Reading

Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects
Human study examining downstream biological effects following activation of the GH/IGF-1 axis.

Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog
Addresses one of the most common concerns regarding DAC technology by examining growth hormone pulsatility.

Once-Daily Administration of CJC-1295, a Long-Acting Growth Hormone-Releasing Hormone Analog, Normalizes Growth in the GHRH Knockout Mouse
Foundational preclinical research supporting the biological rationale behind CJC-1295 development.

Tier 2 — Specialized Applications

Growth hormone releasing hormone (GHRH) physiology
Drug Affinity Complex (DAC) technology
Growth hormone pulsatility and endocrine regulation
IGF-1 biology and downstream signaling
Comparisons between DAC and No DAC formulations

Tier 3 — Controversies, Limitations, and Evidence Gaps

Direct muscle-gain outcomes in healthy adults
Direct recovery outcomes in healthy adults
Long-term consequences of sustained IGF-1 elevation
Receptor desensitization concerns
CJC-1295 DAC and Ipamorelin stacking claims
Athletic performance enhancement claims

CKF Note: The original human pharmacokinetic study often cited as the foundational CJC-1295 DAC paper remains widely referenced in the literature. However, because freely accessible full-text versions are not consistently available to all readers, it is not included in this Further Study section. CKF only recommends resources that can be accessed and reviewed in full without paywalls or account requirements.

CKF Summary: Current evidence strongly supports the ability of CJC-1295 DAC to elevate growth hormone and IGF-1 levels for extended periods. However, many commonly repeated claims regarding muscle gain, recovery enhancement, and peptide-stacking superiority remain supported primarily by anecdotal experience rather than large-scale controlled human trials.

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Endocrinology literature
Peer-reviewed growth hormone and metabolism journals

14. Last Reviewed

June 2026